The "Fast Money" traders share their final trades of the day including Viacom, SPDR S&P 500 Trust ETF (SPY) and more.
The "Fast Money" traders give you 5 ways to trade healthcare stocks following the White House's unveiling of the American Health Care Act.
There's a very good reason market capitalization is still king when it comes to indexing.
UBI could eliminate "poverty traps" that can occur in many of today's welfare schemes, says James Pethokoukis of the AEI.
Major U.S. corporations are going to war in Washington over a Republican "border adjustment" tax proposal meant to boost exports over imports.
Rising tensions between Trump and the Fed have traders scratching their heads.
CNBC's Meg Tirrell reports on a transparency report on drug pricing from drug maker Johnson & Johnson.
Johnson & Johnson lifts lid on drug pricing data. CNBC's Meg Tirrell reports the details. With the "Fast Money Halftime Report" traders.
Johnson & Johnson said the net increase in the cost of its medicines across its portfolio was 3.5 percent.
Wal-Mart Stores is running a price-comparison test in at least 1,200 U.S. stores in a bid to close a pricing gap with its rivals.
Type in "BIGTHANKS" to save some money off of your order.
Buybacks keep rolling along, but here is why they are no panacea for all of the market's problems.
Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers.
By 2030, 70 percent of HIV patients will be over 50. Now success of HIV drugs poses a new challenge: treating it as a geriatric condition.
Traders may want to think twice before backing out of the reflation trade right now.
The earnings boosts fueled by tax cuts may not be quite as great as everyone had hoped.
The Fed is staying as flexible as possible by maintaining a more dovish tone than the markets expected.
More than $270 billion in worldwide mergers and acquisitions were announced in January, but foreign deals with the U.S. are lagging.
Tony Coles, Yumanity Therapeutics CEO, former Onyx CEO, weighs in on President Trump's drug pricing rhetoric and meeting with pharma leaders. With CNBC's Meg Tirrell.
"We have to get the prices down," Trump tells drugmakers at the White House.